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Background: We here report the first investigation of exclusively elective in vitro fertilization (IVF) cycles in women
with no apparent history of infertility. Since IVF outcome in women with infertility are always influenced by
underlying causes of infertility, a study on non-infertile women may offer new insights.
Methods: We investigated 88 females without history of infertility in 109 consecutive elective IVF cycles, almost
exclusively performed for purposes of preimplantation genetic screening (PGS; i.e., elective gender selection). The
following questions were addressed: (i) impact of PGS on IVF pregnancy chances; (ii) impact of transfer of 1 vs. ≥2
embryos on IVF pregnancy chances; (iii) correlation of anti-Müllerian hormone (AMH) levels to embryo ploidy (iv)
effect of gonadotropin dosage used in stimulation on available embryos for transfer; and (v) in form of a 1:1 case
control study, compared 33 elective PGS cycles with matched control cycles without PGS, performed in couples
with either prior tubal ligations and/or severe male factor infertility as indication of IVF.
Results: The overall clinical pregnancy rate for the group was 36.7%; pregnancy was associated with number of
euploid (P = 0.009) and number of embryos transferred (P = 0.001). Odds of pregnancy were 3.4-times higher if ≥4
euploid embryos were produced in comparison to <4 (95% CI 1.2 to 9.2; P = 0.019), and odds of pregnancy were
6.6-times higher if greater than or equal to 2 rather than <1 euploid embryos were transferred (95% CI 2.0 to 21.7;
P = 0.002). Increasing AMH (P = 0.001) and gonadotropin dosage used in ovarian stimulation (P = 0.024), was,
independently, associated with number of available euploid embryos. Increasing AMH, but not follicle stimulating
hormone (FSH), was associated with number of embryos available for biopsy and PGS (P = 0.0001). Implantation
rates were 26.4% with PGS and 9.5% without (P = 0.008). Women undergoing PGS, demonstrated 4.58-times higher
odds of pregnancy than matched controls (95% CI 1.102 to 19.060, Exp 4.584, P = 0.036).
Conclusions: This study suggests that outcomes of elective IVF cycles may significantly deviate from
infertility-associated cycles. Affirming proof of concept for PGS, utilizing day-3 embryo biopsy and fluorescence
in-situ hybridization (FISH), both widely held responsible for earlier failures to establish such proof, suggests that the
principal cause of prior failures were likely not insufficient laboratory techniques but poor patient selection for PGS.
Such a conclusion questions the current reintroduction of PGS with improved techniques and technologies in
absence of prior determination of suited patient populations.
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Clinical utilization of in vitro fertilization (IVF) is almost
exclusive to female and/or male infertility [1]. A rare
exception is IVF in association with preimplantation
genetic diagnosis (PGD), in, otherwise, presumed nor-
mally fertile women [2]. Such IVF cycles are usually
assessed and reported as part of a center’s general IVF
outcome statistics [3].
IVF cycle outcomes can, however, be expected to vary
depending on whether conducted in infertile women or
women with presumed normal fertility. IVF studies in
only non-infertile patient populations, however, do not
exist since they are rare and, therefore, difficult to accu-
mulate at single IVF centers.
Likely for the first time, this study, therefore, reports
on a homogenous cohort of IVF cycles, exclusively per-
formed for non-infertility associated indications. Analyz-
ing such cycles may allow for new insights into IVF
without, otherwise, unavoidable patient biases from
underlying causes of infertility.
One of the most important unresolved issues in IVF is
whether selection of euploid embryo by eliminating
aneuploid embryos before embryo transfer improves
pregnancy rates and reduces miscarriage rates. To
achieve this goal preimplantation genetic diagnosis, in
this indication widely called preimplantation genetic
screening, (PGS) [4], was widely utilized, until shown to
be largely ineffective, and, indeed, reducing pregnancy
chances in older infertile women [5-8]. Largely lacking
underlying causes of infertility, a non-infertile patient
population may, however, be better suited to assess the
validity of PGS.
To assess the value of PGS for embryo selection in
IVF appears of utmost importance because, despite
current consensus that PGS is ineffective [5-8], PGS is
still widely utilized for this indication. This study, there-
fore, attempted to utilize elective IVF cycles in non-
infertile women to assess the value of PGS within a
concept of embryo selection, and for a number of other
unresolved issues in IVF relating to embryo ploidy.
Methods
The study reports on 88 consecutive women undergo-
ing 109 elective IVF cycles involving preimplantation
genetic diagnosis (PGD) for fertility-unrelated indica-
tions (i.e., PGS).
Patient selection
Our center voluntarily follows U.S. national guidelines
for PGS, including most recent opinions of the Ethics
Committee of the American Society of Reproductive
Medicine (ASRM) in regards to elective gender selec-
tion, as summarized by Robertson in 2003 [9], and pub-
lished in updated form by the Committee in 2004 [10].This means that IVF is not performed solely for pur-
poses of gender selection.
IVF is offered in association with PGD for medical
indications, including single gene disorders, parental
translocations, sex-linked diseases, and in medico-social
circumstances, when mental health care providers deter-
mine that circumstances warrant gender selection. Our
center, for example, serves a large gay community, where
a desire for gender selection is common, and supported
by the mental health community. The study, however,
also includes one heterosexual, single female with psy-
chiatric disease, where psychiatric clearance strongly
recommended gender selection for female.
If other medical reasons exist for IVF, gender selection
by PGS may be added if requested by the patient. Exam-
ples include tubal ligation or clinical indications for PGS
(i.e., repeated unexplained aneuploidies in prior preg-
nancies). We currently do not offer PGS for purposes of
embryo selection to improve IVF pregnancy chances
and/or reduce miscarriage rates. In accordance with opi-
nions expressed by the Ethics Committee of ASRM [10],
we have been offering gender selection in non-medical
cases only for family balancing purposes.
In this study we included only women undergoing IVF+
PGS for the purpose of gender selection. Almost all cases
involved elective gender selection for family balancing pur-
poses but 12 cases involved psychiatric recommendations
and three sex-linked diseases. Cycles where PGD was per-
formed for single gene diseases were excluded.
PGD involves analysis of single blastomeres for
chromosomal abnormalities and/or single gene diseases.
As noted, when with the intent of reducing miscarriage
risk and increasing pregnancy chances used to assess
embryo ploidy, the procedure is now described under
the acronym PGS [8].
To qualify for inclusion in this study, women had to
undergo PGS without evidence of a concomitant infertil-
ity diagnosis. A history of tubal ligation or male factor
infertility was, however, permitted since neither affects
IVF outcomes. In cases of semen abnormalities, our cen-
ter uniformly utilizes intracytoplasmic sperm injection
(ICSI) to maximize embryo yields, thus eliminating
potential male factor issues.
Fertility-reducing pathologies in study patients can,
however, not be ruled out. Indeed, a degree of unknown
infertility can be expected in a population, which has
not attempted to conceive. Whatever infertility exists
can be expected to be moderate in degree since PGS
requires minimum embryo numbers, thus precluding
significantly diminished ovarian reserve (DOR). Milder
degrees of DOR, however, had to exist in a significant
number of patients as abnormal anti-Müllerian hormone
(AMH) and follicle stimulating hormone (FSH) levels
demonstrate (Table 1).
Table 1 Comparison of patient characteristics and IVF
cycle outcomes for both patient cohorts
Total cohort Sub-cohort
Patients (n) 88 53
Age (years) 36.8 ± 5.0 35.1 ± 4.5
IVF cycles (n) 109 69
Embryos biopsied (n) 7.0 ± 3.6 6.3 ± 3.5
Euploid embryos (n) 3.6 ± 2.3 3.4 ± 1.0
Embryos transferred (n) 1.7 ± 0.7 1.4 ± 1.0
BMI n/a 23.8 ± 3.7
AMH (ng/mL) n/a 2.3 ± 2.1
FSH (mIU/mL) n/a 9.8 ± 3.8
Estradiol (pg/mL) n/a 47.1 ± 26.0
Total gonadotropin dosage (IU) 4637± 2078
Both patient cohorts did not differ in age and IVF cycle outcomes.
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For 53 patients, undergoing 69 IVF cycles, complete sets
of AMH, FSH and estradiol data were available prior to
first IVF cycle start, as well as total gonadotropin stimu-
lation dosages. This sub-set of patients/cycles was used
to determine how AMH and FSH, as markers of func-
tional ovarian reserve, and gonadotropin dosage used for
ovarian stimulation, relate to embryo ploidy.Control group to assess effectiveness of PGS
To assess potential effects of PGS on pregnancy chances,
a case control group was required, which did not
undergo embryo biopsy and PGS. Controls were selected
from the center’s infertility patient pool but had to have
undergone IVF with principal indication of male factor
infertility. This control group was chosen to isolate,
within the PGS procedure, the potential negative effects
of embryo biopsy on implantation chances, while pre-
serving potential beneficial effects from embryo selec-
tion. Women with secondary diagnoses of polycystic
ovarian syndrome (PCOS) or tubal infertility, were,
therefore, disqualified to preserve controls devoid of po-
tentially additive female infertility causes that could con-
tribute to lower implantation/pregnancy rates.
In addition, age of controls had to be within ± 1 year
of study patients, and ovarian reserve had to be similar,
defined as oocyte yields within ± 2 oocytes. To control
for the laboratory environment and changes in clinical
protocols, all cycles had to be conducted after 2008 since
no significant staff and/or protocol changes have
occurred since.
These strict matching criteria only yielded 25 women,
undergoing 33 IVF cycles (from 109 elective cycles) and
a control group of 28 women. Both groups underwent
33 IVF cycles (25 study patients 1 cycle each, and 4having 2 cycles), while amongst 28 controls, 28 had 1
cycle, 1 had 2, and another 1 underwent 3 cycles.
PGS laboratory technique
Since here presented data represent a retrospective ana-
lysis, the methodology utilized to perform PGS involved
standard techniques and technologies utilized worldwide
during the study period. This means that PGS was per-
formed after day-3 embryo biopsy (6–8 cell stage).
A single blastomere was removed and examined by
fluorescence in situ hybridization (FISH) for seven chro-
mosomes (X, Y, 13, 16, 18, 21, 22).
It, therefore, is important to point out that here uti-
lized techniques and technologies are the same as widely
utilized during initial failed attempts at introduction of
PGS for embryo selection, with purpose of improving
IVF pregnancy rates [5-8].
Clinical cycle management
Ovarian stimulation was uniform: Patients with normal
age-specific ovarian reserve were down-regulated with
luteal phase agonist (leuprolide acetate, LupronTM, Abbot
Pharmaceutical, North Chicago, IL) and stimulated with
between 225–450 IU of follicle stimulating hormone and
human menopausal gonadotropin (hMG), both from dif-
ferent manufacturers. Patients with abnormal ovarian
reserve received microdose agonist (LupronTM), followed
by the same combination of gonadotropins but with
maximal combined dosage of 600 IU daily. All patients
received gonadotropin as FSH, except for 150 IU, given
as hMG.
Normal versus abnormal ovarian reserve was deter-
mined for each patient/cycle based on previously reported
normal age-specific ranges for FSH [11] and AMH [12].
Only clinical intrauterine pregnancies were considered,
with exclusion of chemical pregnancies and ectopic
pregnancies from statistical consideration. A clinical
pregnancy was defined as a normally developing intra-
uterine pregnancy with fetal heart, seen on ultrasound.
Statistical analysis
Since 109 cycles in 88 women were distributed amongst
69 patients with one, 17 with two, and two with three
IVF cycles, all statistical models were adjusted for repeat
cycles.
Categorical data were expressed as numbers and
percentages, and numerical data as mean ± standard
deviation (SD), except when specified. Student’s t-test,
chi - square and Fisher’s exact test were used as appro-
priate. Associations of cycle characteristics with out-
comes of interest were evaluated using logistic regression
analyses, and are reported as odds ratios (OR) and 95%
confidence intervals (95% CI). Significance was defined
as P< 0.05.
Table 2 IVF cycle characteristics for pregnant versus
non-pregnant patients
Pregnant Not pregnant
Percent of total cycles 36.7 63.3
Age (years) 36.5 ± 5.3 37.0 ± 4.6
Embryos biopsied (n) 7.7 ± 3.7 7.0 ± 3.8
≤ 6 n (%) 20 (50.0) 35 (50.7)
≥ 7 n (%) 20 (50.0) 34 (49.3)
Euploid embryos (n)1 4.5 ± 2.4 3.3 ± 2.2
≤ 3 n (%) 16 (40.0) 42 (60.9)
% pregnant 27.6
≥ 4 n (%) 24 (60.0) 27 (39.1)
% pregnant 47.1
Embryos transferred (n) 2.1 ± 0.7 1.6 ± 0.8
≥ 2 euploid embryos available2
n (%) pregnant ET x 1 4/35 (11.4)
n (%) pregnant ET x 2 36/74 (48.6)
Pregnant and non-pregnant women neither differed in age nor in number of
embryo biopsied. 1Logistic regression for pregnancy, adjusted for age and
depending on whether ≥4 or ≤3 euploid embryo were present in cycle,
adjusted by number of embryos biopsied and transferred, demonstrated over
3 fold pregnancy odds in women who had≥ 4 euploid embryos (95% CI 1.224
to 9.201, Exp 3.356, P = 0.019). 2Logistic regression analysis, adjusted for age
cycle number, euploid embryos and depending on whether ≤1 or ≥2 euploid
embryo were transferred demonstrated 6.553-times the odds of pregnancy
with transfer of ≥2 embryos (95 CI 1.979 to 21.695, Exp 6,553, P = 0.002).
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formed to determine independent predictors for clinical
pregnancy. Covariates were included in the adjusted
models, based on evidence of statistical significance to
an association with a respective outcome on univariate
analysis or when plausibility for such a relationship was
obvious. For example, since in the case–control part of
this study gonadotropin dosages and embryo numbers
varied to a significant degree between both groups, both
were included as covariates in the model.
All statistical analyses were performed using the Statis-
tical Package for Social Science, version 19.0 (SPSS Inc.,
Chicago, IL)
Institutional review board
The center’s Institutional Review Board (IRB), for this
study required only expedited review since it involved
only retroactive data/chart review. All patients present-
ing to our center sign at time of first visit an informed
consent, which allows for use of their medical record for
research purposes, as long as the patients’ anonymity
remains protected and the medical record remains confi-
dential. Both conditions were met here. In addition, the
center’s research staff with access to medical records is
under federal HIPAA rules in writing committed to con-
fidentiality. Written informed consents are available for
review by the Editor-in-Chief of this journal.
Results
Table 1 summarizes patient data for all 88 patients and
109 IVF cycle: mean age was 36.8 ± 5.0 years; an average
of 7.0 ± 3.6 embryos were biopsied, of which approxi-
mately half (3.6 ± 2.3) proved euploid; 1.7 ± 0.7 embryos
were transferred.
Table 2 demonstrates that 109 IVF cycles led to 40
pregnancies (36.7%). Pregnant women were non-
significantly younger than of those who failed to con-
ceive. Number of embryos biopsied also did not differ
between pregnant and non-pregnant patients.
Pregnancy chances based on ploidy
As shown in Table 2, pregnant patients, however, pro-
duced significantly more euploid embryos (4.5 ± 2.4 vs.
3.3 ± 2.2; P = 0.009). Logistic regression for clinical preg-
nancy, adjusted for age, number of embryos biopsied
and transferred found that patients who had produced
≥4 euploid embryos demonstrated 3.4-times the odds of
pregnancy in comparison to those with ≤3 euploid
embryos (95% CI 1.2 to 9.2; P = 0.019). This translated
into a clinical pregnancy rate of 47.1% if a cycle resulted
in ≥4 euploid embryos (even if fewer embryos were
transferred, as will be demonstrated below) versus 27.6%
with ≤3 embryos (Figure 1)Pregnancy chances based on number of embryos
transferred
Pregnant patients received significantly more embryos
(2.1 ± 0.7 vs. 1.6 ± 0.8; P = 0.001). Logistic regression,
adjusted for age, attempted cycle number, number of
euploid embryos and depending on whether ≤1 or
≥2 embryos were transferred, demonstrated 6.6-times
the odds of pregnancy with transfer of ≥2 embryos
(95% CI 2.0 to 21.7; P = 0.002). For statistical reasons
patients had to be classified as receiving ≤1 or ≥2
embryos, though no patient, of course, received less than
one embryo.
Factors associated with embryo ploidy
Table 1 also demonstrates that there was no difference
in cycle characteristics between the whole study cohort
of 88 women (and their 109 cycles) and the smaller
study cohort for which AMH, FSH and dosage of
gonadotropin stimulation, were available (53 women,
69 cycles).
This smaller patient group allowed construction of a
model to determine associated patient factors with
embryo euploidy. In a model, adjusted for number of
embryos biopsied, AMH and patient age, increasing
AMH levels and increasing gonadotropin dosages were
significantly associated with increasing numbers of



















































Figure 1 Clinical pregnancy rates depending on number of euploid embryos generated in IVF cycle. Figure 1a demonstrates that patients
who achieved pregnancy produced significantly more euploid embryos (4.5 ± 2.4 vs. 3.3 ± 2.2, P = 0.009), while 1b demonstrates that patients who
in their IVF cycles produced ≥4 euploid embryos, with transfer of similar embryo numbers, produced a 47.5% clinical pregnancy rates, while
patients who only produced ≤3 euploid embryo in their cycle achieved only a 26.6% clinical pregnancy rate, creating for women with ≥4
euploid embryos 3.4-times higher odds of pregnancy (95% CI 1.2 to 9.2; P = 0.019).
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diol related to number of embryos biopsied.Effectiveness of PGS
As Table 3 demonstrates, in the case–control study both
groups were well matched: Ages were 38.7 ± 4.0 and
39.2 ± 4.0 years (range 27.1–45.0 and 27.7–45.4); oocyte
yields 9.7 ± 5.6 and 9.7 ± 5.4 (range for both groups,
2–25); AMH values were 1.5 ± 1.4 and 1.4 ± 1.8 ng/mL,
respectively. None of these values differed between the
two groups.
Total gonadotropin dosages for ovarian stimulation
were 4840 ± 1825 IU in PGS patients and 5934 ± 2330 IU
in controls, a marginally larger dose in the latter group(P = 0.046). Controls also received significantly more
embryos (2.9 ± 1.0 vs. 1.6 ± 0.8; P< 0.0001).
Table 3 also summarizes implantation, pregnancy and
miscarriage rates: Amongst PGS patients, 14/53 (26.4%)
of transferred embryos implanted; in control cycles only
9/95 (9,5%; P = 0.008). Pregnancy rates were higher in
PGS (12/33, 36.4%) than control patients (7/33, 21.2%).
Likely due to small cycle numbers, unadjusted, this dif-
ference did not reach significance. Similarly, miscarriage
rates were lower in PGS cycles (1/12, 8.3%) vs. controls
(1/7, 14.3%) but, likely, because of low miscarriage rates,
this difference did not reach statistical significance,
either.
In PGS cycles logistic regression analysis, adjusted for
age, number of prior IVF cycles, number of embryos
Table 3 Patient/cycle characteristics for case–control
study
PGS Group Control Group
n IVF cycles 30 30
Age (years) 38.7 ± 4.0 39.2 ± 4.0
Range 27.1–45.0 27.7–45.4
AMH (ng/mL) 1.5 ± 1.4 1.4 ± 1.8
Total gonadotropin dosage (IU)2 4840± 1825 5934 ± 2330
Oocyte yields (n) 9.7 ± 5.6 9.7 ± 5.4
Range 2–25 2–25
Embryos transferred (n)1 1.6 ± 0.8 2.9 ± 1.0
Implantation rate (%)3 26.4 9.5
Heartbeats/Embryos transferred 14/53 9/95
Pregnancy rate (%)4 36.4 21.2
n 12/33 7/33
Miscarriage rate (%) 8.3 14.3
n 1/12 1/7
1 Controls had significantly more embryo transferred (P< 0.0001), and 2
utilized marginally more total gonadotropins (P = 0.046). 3 The implantation
rate was significantly higher in PGS cycles (P = 0.008). 4 In univariate analyses
pregnancy rates and miscarriage rates did not differ significantly. After
appropriate adjustments, logistic regression analysis demonstrated 4.58-times
the odds of clinical pregnancy after PGS than in controls (95% CI 1.102 to
19.060, Exp 4.584; P = 0.036).
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however, 4.58-times the odds of achieving a clinical
pregnancy in comparison to controls (95% CI 1.102 to
19.060, P = 0.036).Discussion
Patient ages, FSH, AMH and gonadotropin dosages, uti-
lized for ovarian stimulation, demonstrate that here
investigated patients are neither especially young nor do
they have unusually favorable ovarian reserve. They, in-
deed, appear to represent a rather unfavorable middle-
aged patient population. Especially if not having
attempted conception, as usually the case in couples
desirous of elective gender selection, they will not be
devoid of fertility problems. They, however, still, can be
expected to differ from standard infertile populations,
and, therefore, should demonstrate distinct IVF outcome
variations. Their investigation may, therefore, offer inter-
esting new information.
Though in humans never been proven, improved
embryo aneuploidy should better IVF pregnancy rates,
[8,13]. We previously suggested that a principal reasons
why PGS so far has failed to demonstrate improvements
in IVF outcomes has been poor patient selection [13].
Because aneuploidy increases with advancing female age,
older women, have been widely considered the bestcandidates for PGS [14]. In older women, PGS, however,
was actually demonstrated to reduce pregnancy chances
[7,15]. How can that be?
As noted in the introduction, the principal purpose of
PGS is embryo selection. Older women, however, usually
no longer produce large enough embryo numbers to
warrant embryo selection [13]. They, therefore, end up
with all the downsides of PGS without any of its bene-
fits: decreased implantation/pregnancy chances from
embryo biopsies but no compensatory benefits from
embryo selection.
Considering here studied patients’ ages, their ovarian
reserves (Table 1), that all embryos underwent biopsy
for PGS, known to reduce pregnancy chances [13,16],
and that gender selection results in “loss” of approxi-
mately half of all embryos (the undesired sex), the
observed clinical pregnancy rate of 36.7% per cycle start
is not only excellent but reflective of the national aver-
age IVF pregnancy rate reported in Annual Centers for
Disease Control (CDC) reports. Here utilized patients,
therefore, appear well suited to investigate effects of
ploidy in IVF.
This is further supported by here reported cycle char-
acteristics, for example that women who conceived were
only insignificantly younger than those who did not, had
similar numbers of embryos biopsied and, therefore,
demonstrated no significant differences in oocyte and
embryo yields.
Yet, women who did conceive produced significantly
more euploid embryos (4.5 ± 2.4 vs. 3.3 ± 2.2, P = 0.009).
Availability of ≥4 embryos, in comparison to <4,
resulted in 3.4-times the chance of pregnancy (P = 0.019;
Figure 1), though much fewer embryos were really trans-
ferred (2.1 ± 0.7 in cycle leading to pregnancy and
1.6 ± 0.8 in failed cycles).
All factors being equal, some women, therefore, have
better IVF pregnancy chances because they produce
more euploid embryos than others, independent of age.
Those embryos also exhibit higher pregnancy potential.
The conclusion is that embryo quantity, in principle,
runs in parallel with embryo quality, though specific
conditions, like polycystic ovaries or age, may favor one
or the other. Effectiveness of PGS should, therefore, vary
in different patient populations [13].
In cycles leading to pregnancy significantly more
embryos were transferred (2.1 ± 0.7 vs. 1.6 ± 0.8;
P = 0.001). Logistic regression, adjusted for relevant
confounders, confirmed the importance of numbers
of transferred embryos: Cycles with ≥2 resulted in
6.6-times the pregnancy chance of cycles with only
one transferred embryo (P = 0.002), an observation with
considerable relevance to the currently ongoing debate
about single embryo transfer [17]. Here presented data
confirm that single embryo transfer significantly reduces
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fers [18].
Increasing AMH levels (P = 0.001) and gonadotropin
dosages (P = 0.024) were, independently, associated with
increasing proportions of euploid embryos (i.e., increas-
ing number of normal embryos available for potential
transfer). The AMH association supports reports that
AMH reflects functional ovarian reserve quantitatively
[12] as well as qualitatively [19].
This suggests that FSH and/or AMH ratios per oocyte
or embryo could be predictive of ploidy in eggs and
embryos. We recently, indeed, demonstrated that a ratio
of FSH per oocytes (FSHo) at all ages is constant and
highly predictive of pregnancy with IVF [20]. The poten-
tial benefit of such ratios is also suggested by declining
AMH production per oocyte with advancing female age
[21], and variations of AMH levels per oocyte between
races/ethnicities [22]. Finally, the association of rising
AMH with improving ploidy is also supported by dehy-
droepiandrosterone (DHEA) supplementation in women
with DOR [23], leading to lower embryo aneuploidy [24]
miscarriage rates [25] and higher pregnancy and live
birth chances [26-28].
Here observed positive association between increasing
total gonadotropin dosage for ovarian stimulation and
improving proportions of available euploid embryos for
embryo transfer is important because it contradicts pub-
lished literature in two ways: Some authors, in contrast
to our data, have associated increasing gonadotropin
dosages with increasing aneuploidy rates [29,30]; and
others have claimed that oocyte and embryo yields no
longer improve beyond a rather low ceiling in gonado-
tropin stimulation dosage [31]. These differences may,
indeed, be reflective of differences in investigated patient
populations. Adverse effects of gonadotropin stimulation
on ploidy should not be considered established: In
patients, who spontaneously or after FSH stimulation
conceived, ploidy did not differ [32].
Since daily ovarian stimulation in this study included
150 IU of hMG, here reported findings support previ-
ously reported data (in long agonist protocols) demon-
strating that luteinizing hormone (LH)-containing
stimulation improves ploidy versus stimulation with
pure FSH [33]. FSH, and indirectly LH (through control
over the follicle’s androgen production in theca cells)
[34,35], plays an essential role in early stages of follicle
development. Longer and/or higher gonadotropin expos-
ure may, therefore, beneficially affect follicle maturation.
Just as androgens used to be viewed as damaging to fol-
licle maturation, and are now recognized as essential
[36,37], gonadotropins may, therefore, actually be benefi-
cial to developing follicles and oocytes.
Improving ploidy in transferred embryos has been the
main argument in favor of PGS [4]. Based on PGD/PGSpioneers, like Kuliev and Verlinsky, recommending that
PGS become integral to routine IVF [38], centers around
the world, indeed, initiated routine PGS use until a
Dutch randomized study proved PGS ineffective, and in
older women actually demonstrating that it reduces
pregnancy chances [39]. Since then, utilization of PGS in
attempts of improving IVF pregnancy chances has been
widely discouraged [5-8].
The failure of PGS was widely attributed to inadequate
procedural techniques, especially embryo biopsy (day-3
removal of 1–2 blastomers) and aneuploidy detection by
fluorescent in-situ hybridization (FISH) [16]. Others,
however, pointed towards poor patient selection as prin-
cipal cause [8,13]. Currently ongoing active efforts at
reintroducing PGS into routine IVF, this time utilizing
improved techniques and technologies [40], stresses the
urgency of resolving this conflict, as any such reintro-
duction is, likely, bound to fail again if patient selection,
indeed, proves to have been the decisive factor in the
earlier PGS failure.
The case–control part of this study was designed to
resolve this issue: If, indeed, inadequate techniques and
technologies had been responsible for the initial PGS
failure, we should be unable to establish proof of con-
cept for PGS, utilizing FISH and day-3 embryo biopsy in
this study. Confirmation proof of concept for PGD
would, however, strongly suggest that patient selection
was the cause.
In a retroactive analysis, elective IVF cycles require
well-matched controls [41]. Choosing rigidity of the
matching process over study size, only 33 of originally
108 elective IVF cycles could be properly matched.
Here reported statistically significant results, however,
validate this approach. Though small in size, this sub-
study, nevertheless, confirmed proof of concept: Embryo
selection by PGS, indeed, improved embryo implanta-
tion rates and pregnancy chances by demonstrating that
in age-matched patient cycles (with identical ovarian
reserve), implantation rates were significantly higher
after PGS (P = 0.008).
Likely due to the small study size, pregnancy rates in
univariate analysis missed significance. Appropriate stat-
istical adjustments for number of embryos transferred
and gonadotropin dosages (both significantly different
by univariate analysis, Table 3) and repeat cycles,
demonstrated, however, that the odds of pregnancy were
actually 4.58-times higher after PGS (P = 0.036).
Considering the small study size, these results are sur-
prisingly robust statistically. Since definition of miscarriage
required prior fetal heart activity, and so-called missed
abortion, therefore, were not considered, it would be
unrealistic to expect significant results in regards to preg-
nancy loss. Missed abortions in a majority, represent aneu-
ploid pregnancies [42]. Their inclusion, therefore, even in
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benefit from PGS on pregnancy loss. This is supported by
the observed 14.3% miscarriage rate in controls, represent-
ing the expected miscarriage rate in a general population
after spontaneous conception [43], while PGS patients, at
8.3%, demonstrated almost half the rate.
This first study ever exclusively performed in elective
IVF cycles, thus, offers new information on a number of
important unresolved issues: (i) Embryo ploidy varies
between women, even when controlled for covariates,
such as age and ovarian reserve. Moreover, since preg-
nancy potential of euploid embryos also varies between
women, ploidy is not the only pregnancy-determining
factor; (ii) Single embryo transfer significantly reduces
pregnancy chances in comparison to ≥2 embryos; (iii)
Increasing AMH levels reflect increasing euploid embryo
numbers, confirming AMH as a quantitative as well as
qualitative assessment; (iv) Available euploid embryos
actually increase with increasing gonadotropin dosages,
suggesting that up to 600 IU daily may contribute to
better IVF pregnancy rates; and (v) Embryo selection via
PGS in properly selected patients can, indeed, improve
embryo implantation and IVF pregnancy rates and will,
likely, also reduce miscarriage rates.
Confirmation of proof of concept for PGS with use
of traditional techniques and technologies suggests that
the original worldwide clinical failure of PGS was based
on patient selection, and not inadequate techniques
and technologies. Newly proposed embryo biopsy tim-
ing (trophectoderm biopsy day-5, blastocyst-stage) and
improved ploidy assessment technologies (arrays, offer-
ing assessments of all chromosomes), therefore, will be
unlikely to beneficially affect the clinical utility of PGS
in association with IVF.
One, of course, would have preferred a prospectively
randomized study having led to these conclusion but
prospectively randomized studies in IVF are often very
difficult, if not impossible, to perform [41]. An eagerly
anticipated clinical trial of PGS under the auspices of
the European Society for Human Reproduction and Em-
bryology (ESHRE) has been announced [44]. Until
results of properly conducted clinical trials become
available, other study formats have to be accepted as
best available evidence [41]. Here presented data in form
of a rigorous case control study, currently, therefore rep-
resent best available evidence, even in comparison to lar-
ger, uncontrolled studies.
Any retroactive analysis of outcome data is, of course,
open to unrecognized biases. While non-infertile women
in elective IVF cycles avoid many selection biases of in-
fertile patients, even such a patient population cannot
avoid all biases.
Further studies are required to better define patient
populations, which will benefit from PGS. To prevent asecond premature introduction of PGS, the procedure
experimental, and should be offered only with experi-
mental informed consent, and under study conditions.
Conclusions
This study for the first time presents an IVF experience
of exclusively elective not-infertility related cycles. Such
cycles in some aspects vary from what has been reported
for IVF cycles in infertile women, suggesting that, in
interpreting IVF outcomes, current literature may not
always properly differentiate between outcome contribu-
tions from underlying infertility and the IVF procedure,
itself. Utilizing day-3 embryo biopsy and FISH, the study
also established proof of concept that, in properly selected
patients, PGS, indeed, improves pregnancy chances with
IVF and, likely, reduces miscarriage risk. This observation
suggests that earlier failures in proving the efficacy of
PGS were, likely not the result of poor techniques and
technologies, as has been suggested, but the consequence
of poor patient selection.
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